These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 26314849)

  • 1. A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer.
    Moon JH; Shin JS; Hong SW; Jung SA; Hwang IY; Kim JH; Choi EK; Ha SH; Kim JS; Kim KM; Hong DW; Kim D; Kim YS; Kim JE; Kim KP; Hong YS; Choi EK; Lee JS; Hattersley M; Jin DH; Kim TW
    Oncotarget; 2015 Sep; 6(29):26895-908. PubMed ID: 26314849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of cIAP1 and XIAP in Apoptosis Induced by Tumor Necrosis Factor Alpha in Esophageal Squamous Cell Carcinoma Cells.
    Hikami S; Shiozaki A; Kitagawa-Juge M; Ichikawa D; Kosuga T; Konishi H; Komatsu S; Fujiwara H; Okamoto K; Otsuji E
    Dig Dis Sci; 2017 Mar; 62(3):652-659. PubMed ID: 28050781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells.
    Hong SW; Shin JS; Moon JH; Jung SA; Koh DI; Ryu Y; Park YS; Kim DY; Park SS; Hong JK; Kim EH; Kim MJ; Jeong HR; Bae IH; Ahn YG; Suh KH; Cho IJ; Kang JS; Hong YS; Lee JS; Jin DH; Kim TW
    Invest New Drugs; 2020 Dec; 38(6):1696-1706. PubMed ID: 32462369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous XIAP and cIAP1/2 inhibition by a dimeric SMAC mimetic AZD5582 induces apoptosis in multiple myeloma.
    Kikuchi S; Sugama Y; Takada K; Kamihara Y; Wada A; Arihara Y; Nakamura H; Sato T
    J Pharmacol Sci; 2024 Jan; 154(1):30-36. PubMed ID: 38081681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma.
    Su K; Yuan Q; Hou H; Ke C; Huang C; Li S; Sun J; Yuan X; Lin Y; Chen Y; Xin H; Liang X; Du Z; Yuan Z
    J Mol Med (Berl); 2022 Apr; 100(4):629-643. PubMed ID: 35247069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor-α-induced apoptosis of gastric cancer MKN28 cells: accelerated degradation of the inhibitor of apoptosis family members.
    Kitagawa M; Shiozaki A; Ichikawa D; Nakashima S; Kosuga T; Konishi H; Komatsu S; Fujiwara H; Okamoto K; Otsuji E
    Arch Biochem Biophys; 2015 Jan; 566():43-8. PubMed ID: 25513960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoprotective effects of IAPs revealed by a small molecule antagonist.
    Galbán S; Hwang C; Rumble JM; Oetjen KA; Wright CW; Boudreault A; Durkin J; Gillard JW; Jaquith JB; Morris SJ; Duckett CS
    Biochem J; 2009 Feb; 417(3):765-71. PubMed ID: 18851715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling.
    Takeuchi H; Kim J; Fujimoto A; Umetani N; Mori T; Bilchik A; Turner R; Tran A; Kuo C; Hoon DS
    Clin Cancer Res; 2005 Nov; 11(21):7621-8. PubMed ID: 16278380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.
    Jiang C; Yi XP; Shen H; Li YX
    World J Gastroenterol; 2012 Jun; 18(23):2956-65. PubMed ID: 22736919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
    Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
    Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lentivirus-mediated shRNA targeting XIAP and survivin inhibit SW1990 pancreatic cancer cell proliferation in vitro and in vivo.
    Jiang C; Tan T; Yi XP; Shen H; Li YX
    Mol Med Rep; 2011; 4(4):667-74. PubMed ID: 21479361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death.
    Yamaguchi Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Saitou Y; Sugimoto K; Nakano T
    Oncol Rep; 2005 Nov; 14(5):1311-6. PubMed ID: 16211302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.
    Kour S; Rana S; Contreras JI; King HM; Robb CM; Sonawane YA; Bendjennat M; Crawford AJ; Barger CJ; Kizhake S; Luo X; Hollingsworth MA; Natarajan A
    Mol Pharmacol; 2019 Oct; 96(4):419-429. PubMed ID: 31467029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.
    Sun H; Lu J; Liu L; Yang CY; Wang S
    ACS Chem Biol; 2014 Apr; 9(4):994-1002. PubMed ID: 24521431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER).
    Ohoka N; Ujikawa O; Shimokawa K; Sameshima T; Shibata N; Hattori T; Nara H; Cho N; Naito M
    Chem Pharm Bull (Tokyo); 2019 Mar; 67(3):203-209. PubMed ID: 30369550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor of Apoptosis Protein-1 Regulates Tumor Necrosis Factor-Mediated Destruction of Intestinal Epithelial Cells.
    Grabinger T; Bode KJ; Demgenski J; Seitz C; Delgado ME; Kostadinova F; Reinhold C; Etemadi N; Wilhelm S; Schweinlin M; Hänggi K; Knop J; Hauck C; Walles H; Silke J; Wajant H; Nachbur U; W Wei-Lynn W; Brunner T
    Gastroenterology; 2017 Mar; 152(4):867-879. PubMed ID: 27889570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UVB-induced anti-survival and pro-apoptotic effects on HaCaT human keratinocytes via caspase- and PKC-dependent downregulation of PKB, HIAP-1, Mcl-1, XIAP and ER stress.
    Park YK; Jang BC
    Int J Mol Med; 2014 Mar; 33(3):695-702. PubMed ID: 24356997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRAIL-Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582).
    Hou H; Su K; Huang C; Yuan Q; Li S; Sun J; Lin Y; Du Z; Ke C; Yuan Z
    Adv Healthc Mater; 2021 Jun; 10(11):e2100030. PubMed ID: 33963815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.